April 19, 2002 |
Retired Gen. Norman Schwarzkopf, diagnosed with prostate cancer, said it best: "You cannot sit back and do nothing because you'll never have perfect intelligence on the enemy. ... Get on with it. " Prostate cancer is the most commonly diagnosed malignancy in American men. It's curable if diagnosed early; if not, there's presently no cure. Early detection is the key. More than 30,000 will die from the disease this year alone. One out of every 18 of those deaths will come to a Pennsylvania resident - ranking the state fifth in the number of both cases and deaths.
February 1, 2013 |
Only 10 percent of men treated for early prostate cancer could sustain an erection sufficient for sex 15 years later, according to a study that found impotence rates were the same whether treatment was surgery or radiation. The findings were produced by the longest and broadest look at quality-of-life outcomes in two common therapies for prostate cancer. Researchers repeatedly surveyed 1,655 men diagnosed with localized disease and given surgery or external beam radiation. While surgery patients had higher impotence rates two years after treatment, by 15 years erection failure "was nearly universal" with both treatments, according to the study published Thursday in the New England Journal of Medicine.
November 26, 2012 |
Question: I recently had a prostate biopsy, which showed a small area of cancer. My urologist discussed the option of close surveillance, with periodic biopsies and regular PSA blood testing. I'm 65 years old and otherwise in great health. Do you think it's better to treat the cancer or just watch it? Answer: In the case of early prostate cancer like you have, "active surveillance" is a reasonable approach. The downsides are the uncertainty of the disease course and the anxiety of living with prostate cancer.
May 23, 2012 |
In rejecting PSA screening for prostate cancer, an influential federal panel has chipped a cornerstone of preventive medicine, declaring that it's not always best to catch cancer as early as possible. "At best, PSA screening may help only 1 man in 1,000 avoid death from prostate cancer," the U.S. Preventive Services Task Force said Monday. "Most prostate cancers found by PSA screening are slow growing, not life threatening, and will not cause a man any harm during his lifetime.
October 7, 2011 |
Healthy men should no longer receive a PSA blood test to screen for prostate cancer because the test does not save lives over all and often leads to more tests and treatments that needlessly cause pain, impotence, and incontinence in many, a key government health panel concluded. The recommendation, by the United States Preventive Services Task Force and due for official release early next week, is based on the results of five well-controlled clinical trials and could substantially change the care given to men 50 and older.
April 4, 2013 |
ALLENTOWN - The Lehigh Valley IronPigs are truly No. 1 when it comes to the adventurous new world of urinal gaming. The IronPigs have created a video game that has what they call the "only truly hands-free urinal game controller. " It doesn't take much to be a whiz at this game, which is featured in the men's restrooms at Coca-Cola Park. The new game likely won't hurt the sales of beverages, since the extra fluids will give the participants staying power. "These games are sure to make a huge splash," quipped IronPigs general manager Kurt Landes, who has labeled them "The X-Stream Games.
October 13, 2011 |
Terry Dyroff's PSA blood test led to a prostate biopsy that didn't find cancer but gave him a life-threatening infection. In the emergency room several days later, "I didn't sit, I just laid on the floor, I felt so bad," said Dyroff, 65, a retired professor from Silver Spring, Md. "I honestly thought I might be dying. " Donald Weaver was a healthy 74-year-old Kansas farmer until doctors went looking for prostate cancer. A PSA test led to a biopsy and surgery, then a heart attack, organ failure, and coma.
December 5, 2013 |
The family of a University of Pennsylvania neuroscientist who died of brain cancer sued the university Tuesday, alleging that the school bore responsibility for his death by failing to protect him from laboratory radiation. The family of Jeffrey H. Ware further alleged that Penn physicians enrolled him in a study without proper consent, treating his gliosarcoma with still more radiation, thereby subjecting him to painful side effects long after there was any hope of recovery. Ware, who died in October 2011 at age 47, lived in Haddonfield.
January 12, 2012 |
DURHAM, N.C. - A good set of headphones and a little Bach may ease the pain and anxiety of getting a prostate biopsy, according to a newly published study by Duke Cancer Institute researchers. That could be music to the ears of the 700,000 American men who each year get the often-uncomfortable procedure, regarded as the only reliable diagnostic test for prostate cancer. Results of the study were published this month in the journal Urology. Researchers enrolled 88 patients and randomly assigned each to one of three groups.
January 31, 1989 |
PROSTATE-CANCER DRUG. The Food and Drug Administration has approved use of a hormone-blocking drug to help slow the progress of prostate cancer and improve the lives of its victims. The drug, flutamide, will be sold by Schering-Plough Corp. under the name Eulexin. The FDA said a recent National Cancer Institute study found that patients taking both flutamide and leuprolide - a drug already on the U.S. market under the name Lupron - survived an average of 34.9 months, or nearly 25 percent, longer than patients taking leuprolide alone.